Walleye Capital’s Karuna Therapeutics, Inc. Common Stock KRTX Stock Holding History

Walleye Capital’s Portfolio KRTX Stock Details KRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-700	Closed	-$222K	–	6086
2023 Q4	$222K	Sell	700 -400	-36%	-$77.8K	﹤0.01%	3615
2023 Q3	$186K	Sell	1,100 -3,000	-73%	-$564K	﹤0.01%	3601
2023 Q2	$889K	Sell	4,100 -800	-16%	-$171K	﹤0.01%	1953
2023 Q1	$890K	Buy	4,900 +300	+7%	+$57.4K	0.01%	1248
2022 Q4	$904K	Sell	4,600 -800	-15%	-$172K	0.02%	1058
2022 Q3	$1.22M	Buy	+5,400	New	+$1.09M	0.02%	838

Other funds holding KRTX

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return

Walleye Capital's KRTX Position: Q1 2023 in Review

Walleye Capital sold out of Karuna Therapeutics, Inc. Common Stock (KRTX) in Q1 2023, closing a stake of 6,605 shares — an estimated $1.26M sold.

Walleye Capital first reported a position in KRTX in Q1 2022 and held it in 2 quarters. The position peaked at $3.85M in Q1 2022. 246 funds tracked by Wall St. Rank hold KRTX as of Q1 2023.

Walleye Capital reported no remaining Karuna Therapeutics, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
Walleye Capital sold 6,605 Karuna Therapeutics, Inc. Common Stock shares in Q1 2023, an estimated $1.26M.
Walleye Capital first reported a position in Karuna Therapeutics, Inc. Common Stock in Q1 2022 and held it in 2 quarters.
Walleye Capital's Karuna Therapeutics, Inc. Common Stock position peaked at $3.85M in Q1 2022.
246 funds tracked by Wall St. Rank held Karuna Therapeutics, Inc. Common Stock as of Q1 2023.

Based on Walleye Capital's 13F filing for Q1 2023, filed 15 May 2023.